Alexander Mansour, MBA
Advertisement
Articles by Alexander Mansour, MBA
The Centers for Medicare and Medicaid Services finalized a ruling that slashes reimbursement rates on drugs that qualify under the 340B program.
Advertisement
Latest Updated Articles
- Opinion: CMS 340B Reimbursement Cuts Cause Big Pharma Profits While Underserved Patients Lose
Published: January 4th 2018 | Updated:
Opinion: CMS 340B Reimbursement Cuts Cause Big Pharma Profits While Underserved Patients LosePublished: January 3rd 2018 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Announces Recall 580,000 Bottles of Prazosin Over Potential Carcinogenic Impurity
2
Experimental Vaccine Shows 73% Efficacy Against Salmonella Paratyphi A
3
Pharmacists Key to Counseling and Monitoring Patients Transitioning to Low-Sodium Oxybate
4
